Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib vs Sorafenib in First-Line Unresectable HCC
NCT01761266Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd.. Started Mar 2013; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01761266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01761266.